Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 21 articles: HTML format

Single Articles

June 2025
1. STITZ R, Stoiber F, Silye R, Rebhan E, et al
   Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.
   Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019.
   PubMed     Abstract available
   
   
   
2. SAWADA Y, Kikugawa T, Onishi T, Arai O, et al
   CTHRC1 promotes bone metastasis in prostate cancer.
   Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012.
   PubMed     Abstract available
   
   
   December 2024
3. SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al
   Life expectancy in rare histological prostate cancer subtypes.
   Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323.
   PubMed     Abstract available
   
   
   
4. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
   Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
   Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
   PubMed     Abstract available
   
   
   October 2024
5. GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al
   Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.
   Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208.
   PubMed     Abstract available
   
   
   September 2024
6. MOGHUL M, Tran A, Croft F, Kinsella N, et al
   The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
   Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
   PubMed     Abstract available
   
   
   July 2024
7. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
   Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
   Int J Cancer. 2024;155:314-323.
   PubMed     Abstract available
   
   
   June 2024
8. HUANG CY, Huang CP, Huang YY, Huang SK, et al
   Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
   Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040.
   PubMed     Abstract available
   
   
   
9. SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al
   Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
   Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052.
   PubMed     Abstract available
   
   
   April 2024
10. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    PubMed     Abstract available
    
    
    
11. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    PubMed     Abstract available
    
    
    March 2024
12. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    PubMed     Abstract available
    
    
    
13. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    PubMed     Abstract available
    
    
    
14. ZHANG Y, Stopsack KH, Song M, Mucci LA, et al
    Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898.
    PubMed     Abstract available
    
    
    February 2024
15. CARUANA M, Gulati R, Etzioni R, Barratt A, et al
    Benefits and harms of prostate specific antigen testing according to Australian guidelines.
    Int J Cancer. 2024;154:648-658.
    PubMed     Abstract available
    
    
    January 2024
16. SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al
    The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
    Int J Cancer. 2024;154:261-272.
    PubMed     Abstract available
    
    
    
17. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    November 2023
18. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    PubMed     Abstract available
    
    
    
19. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    PubMed     Abstract available
    
    
    
20. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    PubMed     Abstract available
    
    
    October 2023
21. ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al
    The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.